Effect of adjunct metformin treatment on levels of plasma lipids in patients with type 1 diabetes

Diabetes, Obesity and Metabolism

Volumn 11, Issue 10, 2009, Pages 966-977

  Lund, S S ^a   Tarnow, L ^a   Astrup, A S ^a   Hovind, P ^a   Jacobsen, P K ^a   Alibegovic, A C ^a   Parving, I ^a   Pietraszek, L ^a   Frandsen, M ^a   Rossing, P ^a   Parving, H H ^b,c   Vaag, A A ^d  

^a STENO DIABETES CENTER   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c AARHUS UNIVERSITY   (Denmark)

^d LUND UNIVERSITY   (Sweden)

Author keywords

Cholesterol; LDL cholesterol; Lipids; Metformin; Statins; Type 1 diabetes mellitus

Indexed keywords

ATORVASTATIN; FISH OIL; FLUINDOSTATIN; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; PLACEBO; PRAVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL;

ADJUVANT THERAPY; ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GLYCEMIC CONTROL; HUMAN; HYPERCHOLESTEROLEMIA; INSULIN DEPENDENT DIABETES MELLITUS; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; RANDOMIZED CONTROLLED TRIAL;

ADULT; CHOLESTEROL; DIABETES MELLITUS, TYPE 1; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; MIDDLE AGED;

EID: 70349762895     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2009.01079.x     Document Type: Article

References (46)

1. Schramm TK, Gislason GH, Kober L. Diabetes patients requiring glucose-lowering therapy and nondiabetics with a prior myocardial infarction carry the same cardiovascular risk: a population study of 3.3 million people. Circulation 2008, 117:1945-1954.
2. Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998, 339:229-234.
3. Ryden L, Standl E, Bartnik M. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J 2007, 28:88-136.
4. Sgambato S, Varricchio M, Tesauro P, Passariello N, Carbone L. [The use of metformin in ischemic cardiopathy]. Clin Ter 1980, 94:77-85.
5. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998, 352:854-865.
6. Wulffele MG, Kooy A, de Zeeuw D, Stehouwer CD, Gansevoort RT. The effect of metformin on blood pressure, plasma cholesterol and triglycerides in type 2 diabetes mellitus: a systematic review. J Intern Med 2004, 256:1-14.
7. Lund SS, Tarnow L, Frandsen M. Impact of metformin versus the prandial insulin secretagogue, repaglinide, on fasting and postprandial glucose and lipid responses in non-obese patients with type 2 diabetes. Eur J Endocrinol 2008, 158:35-46. Erratum: 2008; 158: 443-5
8. Bolen S, Feldman L, Vassy J. Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. Ann Intern Med 2007, 147:386-399.
9. Nathan D, Buse J, Davidson M. Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy. Diabetologia 2009, 52:17-30.
10. Laing SP, Swerdlow AJ, Slater SD. Mortality from heart disease in a cohort of 23,000 patients with insulin-treated diabetes. Diabetologia 2003, 46:760-765.
11. Nathan DM, Cleary PA, Backlund JY. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005, 353:2643-2653.
12. Särnblad S, Kroon M, Aman J. Metformin as additional therapy in adolescents with poorly controlled type 1 diabetes: randomised placebo-controlled trial with aspects on insulin sensitivity. Eur J Endocrinol 2003, 149:323-329.
13. Moon RJ, Bascombe LA, Holt RI. The addition of metformin in type 1 diabetes improves insulin sensitivity, diabetic control, body composition and patient well-being. Diabetes Obes Metab 2007, 9:143-145.
14. Khan AS, McLoughney CR, Ahmed AB. The effect of metformin on blood glucose control in overweight patients with type 1 diabetes. Diabet Med 2006, 23:1079-1084.
15. Meyer L, Bohme P, Delbachian I. The benefits of metformin therapy during continuous subcutaneous insulin infusion treatment of type 1 diabetic patients. Diabetes Care 2002, 25:2153-2158.
16. Hamilton J, Cummings E, Zdravkovic V, Finegood D, Daneman D. Metformin as an adjunct therapy in adolescents with type 1 diabetes and insulin resistance: a randomized controlled trial. Diabetes Care 2003, 26:138-143.
17. Pagano G. Metformin reduces insulin requirement in type 1 (insulin-dependent) diabetes. Diabetologia 1983, 24:351-354.
18. Gin H. Metformin improved insulin resistance in type I, insulin-dependent, diabetic patients. Metabolism 1985, 34:923-925.
19. Janssen M, Rillaerts E, De LI. Effects of metformin on haemorheology, lipid parameters and insulin resistance in insulin-dependent diabetic patients (IDDM). Biomed Pharmacother 1991, 45:363-367.
20. Lacigova S, Rusavy Z, Jankovec Z, Kyselova P. Metformin in the treatment of type 1 diabetics - a placebo controlled study. Cas Lek Cesk 2001, 140:302-306.
21. Lund SS, Tarnow L, Astrup AS. Effect of adjunct metformin treatment in patients with type-1 diabetes and persistent inadequate glycaemic control. A randomized study. PLoS ONE 2008, 3:e3363.
22. Friedewald WT, Levy RI, Frederickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifugation. Clin Chem 1972, 18:499-502.
23. Kahn SE, Haffner SM, Heise MA. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006, 355:2427-2443.
24. Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the diabetes prevention program. Diabetes Care 2005, 28:888-894.
25. Carlsen SM, Rossvoll O, Bjerve KS, Følling I. Metformin improves blood lipid pattern in nondiabetic patients with coronary heart disease. J Intern Med 1996, 239:227-233.
26. Misra P. AMP activated protein kinase: a next generation target for total metabolic control. Expert Opin Ther Targets 2008, 12:91-100.
27. Zang M, Zuccollo A, Hou X. AMP-activated protein kinase is required for the lipid-lowering effect of metformin in insulin-resistant human HepG2 cells. J Biol Chem 2004, 279:47898-47905.
28. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. Br Med J 2003, 326:1423-1427.
29. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 2008, 371:117-125.
30. Collins R, Armitage J, Parish S, Sleigh P, Peto R. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003, 361:2005-2016.
31. Alemao E, Yin D, Sintonen H, Salomaa V, Jousilahti P. Evaluation of lipid-lowering therapy and cholesterol goal attainment in Finland: the National FINRISK Study. Am J Cardiovasc Drugs 2006, 6:349-355.
32. Jacobs MJ, Kleisli T, Pio JR. Prevalence and control of dyslipidemia among persons with diabetes in the United States. Diabetes Res Clin Pract 2005, 70:263-269.
33. Davidson MH, Ballantyne CM, Kerzner B. Efficacy and safety of ezetimibe coadministered with statins: randomised, placebo-controlled, blinded experience in 2382 patients with primary hypercholesterolemia. Int J Clin Pract 2004, 58:746-755.
34. Kastelein JJP, Akdim F, Stroes ESG. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 2008, 358:1431-1443.
35. Rossebo AB, Pedersen TR, Boman K. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med 2008, 359:1343-1356.
36. Despres JP, Lamarche B, Mauriege P. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med 1996, 334:952-957.
37. Calle EE, Thun MJ, Petrelli JM, Rodriguez C, Heath CW. Body-mass index and mortality in a prospective cohort of U.S. adults. N Engl J Med 1999, 341:1097-1105.
38. Willett WC, Dietz WH, Colditz GA. Guidelines for healthy weight. N Engl J Med 1999, 341:427-434.
39. Yusuf S, Hawken S, Ounpuu S. Obesity and the risk of myocardial infarction in 27 000 participants from 52 countries: a case-control study. Lancet 2005, 366:1640-1649.
40. Standards of medical care in diabetes - 2006. Diabetes Care 2006, 29(Suppl. 1):S4-S42.
41. Jeppesen J. Relation of high TG-low HDL cholesterol and LDL cholesterol to the incidence of ischemic heart disease. An 8-year follow-up in the Copenhagen Male Study. Arterioscler Thromb Vasc Biol 1997, 17:1114-1120.
42. Jeppesen J. Triglyceride concentration and ischemic heart disease: an eight-year follow-up in the Copenhagen Male Study. Circulation 1998, 97:1029-1036.
43. Barter PJ, Caulfield M, Eriksson M. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007, 357:2109-2122.
44. Frikke-Schmidt R, Nordestgaard BG, Stene MCA. Association of loss-of-function mutations in the ABCA1 gene with high-density lipoprotein cholesterol levels and risk of ischemic heart disease. JAMA 2008, 299:2524-2532.
45. Taskinen MR. Diabetic dyslipidaemia: from basic research to clinical practice. Diabetologia 2003, 46:733-749.
46. Wadden TA. Two-year changes in lipids and lipoproteins associated with the maintenance of a 5% to 10% reduction in initial weight: some findings and some questions. Obes Res 1999, 7:170-178.